Abstract 4311: The interplay of SYNCRIP deficiency, APOBEC activity, and extrachromosomal DNA in castration-resistant prostate cancer drug resistance
Li X, Deng S, Wang C, Wang Y, Mu P. Abstract 4311: The interplay of SYNCRIP deficiency, APOBEC activity, and extrachromosomal DNA in castration-resistant prostate cancer drug resistance. Cancer Research 2024, 84: 4311-4311. DOI: 10.1158/1538-7445.am2024-4311.Peer-Reviewed Original ResearchProstate cancer drug resistanceCancer drug resistanceDrug resistanceProstate cancerTherapy resistanceAmerican Association for Cancer Research annual meetingsResistance to androgen receptor (AR)-targeted therapiesAndrogen receptor (AR)-targeted therapiesIncreased therapy resistanceTumor mutational burdenCRPC cell linesAPOBEC activityCastration-resistant formComplexity of drug resistanceWhole-exome sequencingContribution to drug resistanceDrivers of resistanceIn vivo modelsPatient-derived samplesExtrachromosomal DNAAPOBEC-mediated mutagenesisMutational burdenDNA damageFunctional CRISPR screensTumor behavior
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply